 |
|
 |
 |

Weight loss improves health in patients with type 2 diabetes. It has been shown to ameliorate
insulin resistance, to improve carbohydrate tolerance and to reduce hyperglycemia and
hyperinsulinemia. 5
Published studies have shown that serum glucose levels began to improve within days after
starting a weight-loss program even on a moderately hypocaloric (1200 to 1500 calories/day)
diet.48 Weight reduction in patients with type 2 diabetes also lead to increases in HDL
cholesterol levels.5
XENICAL is indicated for obesity management in patients with an initial body mass index (BMI)
of 30 or more and in patients with a BMI of 27 or more in the presence of other risk factors
(e.g., hypertension, diabetes, dyslipidemia). After 6 months, 72% of patients lost 5% or more
of their initial body weight, with a mean loss of 23 lbs. Weight loss has been shown to reduce
or eliminate the need for diabetic drug therapy.47 It has also been demonstrated in a modest
number of studies to improve abnormally low insulin sensitivity and coronary risk promoting
plasma lipoprotein levels found in obese subjects with the prediabetic condition known as
syndrome X.21,22
Specific Health Benefits:
Population with Abnormal (Untreated) Risk Factors at Randomization
Weight Loss with XENICAL Plus Diet: Improved Fasting Insulin
- In patients with abnormal baseline values of fasting insulin (>120 pmol/L), weight loss
with XENICAL plus diet resulted in a greater decrease in fasting insulin than placebo (-39
pmol/L vs. 16 pmol/L, respectively) from randomization to 1 year.
Population as a Whole
XENICAL Plus Diet: Successful Weight Loss
In clinical trials involving 1064 patients, 69% on XENICAL plus diet lost 3% or more of initial
body weight within 3 months, with a mean loss of 13 lbs.
The mean change in fasting insulin was 6.7 pmol/L for patients on XENICAL plus diet and +0.58
for patients on placebo plus diet.
In clinical trials, the overall mean weight loss from randomization to the end of 1 year in the
intent-to-treat population was 13.4 lbs in patients treated with XENICAL plus diet versus 5.8 lbs
in placebo-treated patients.
The long-term effects of orlistat on morbidity and mortality associated with obesity have not
been established.
Managing Patients with Obesity-Related Comorbidities
More about Obesity as a Clinical Condition
|
 |
|